PDE-5 is overexpressed in pulmonary circulation smooth muscle cells in patients with PAH, and forms the basis for treating PAH with PDE-5 inhibitors (PDE-5is) [21]. This evidence concerns the gene PDE5A and pulmonary arterial hypertension.